Introduction
============

Children in the pediatric intensive care unit (PICU) are at high risk of hospital-acquired infection. Ventilator-associated pneumonia (VAP) is the most common hospital-acquired infection, with an incidence of 8--28% ([@b1-etm-05-01-0367],[@b2-etm-05-01-0367]). VAP is becoming a common and fatal complication as mechanical ventilation is being increasingly used in the PICU. VAP is defined as pneumonia occurring \>48 h after patients have accepted intubation and received mechanical ventilation. It often presents as deteriorated pneumonia or as new foci in the lungs. The occurrence rate in adults reaches 9--27% and the mortality rate is 20--50% ([@b3-etm-05-01-0367]--[@b5-etm-05-01-0367]). In children, due to their poor immunity, serious original disease and prolonged mechanical ventilation, the mortality rate of 24--76% is higher than in adults ([@b1-etm-05-01-0367],[@b2-etm-05-01-0367]). In order to study the epidemiology and changes in antibacterial susceptibility to allow guidance of the empirical and reasonable use of antibiotics to reduce the mortality of children with VAP, we retrospectively studied the pathogenic bacteria distribution and drug resistance in 121 VAP patients in the PICU of the Children's Hospital affiliated to Zhejiang University from January 2007 to December 2011.

Patients and methods
====================

Patients
--------

From January 2007 to December 2011, a total of 492 patients underwent mechanical ventilation and of these, 121 patients developed VAP. From these patients 127 strains were isolated. The general data of the 121 children (whose ages ranged from 2 months to 16 years, 3 months; median age 3 years, 6 months) are shown in [Table I](#t1-etm-05-01-0367){ref-type="table"}. The present study was approved by the ethics committee of the Children's Hospital of Zhejiang University School of Medicine and informed consent was obtained from all patients.

Definition of VAP
-----------------

The diagnostic criteria of VAP are as follows: i) pneumonia occurring more than 48 h after intubation and mechanical ventilation; ii) two or more of the following four criteria: a) fever \>38.3°C; b) leukocytosis \>10,000 cells/ml or \<5,000 cells/ml; c) purulent tracheobronchial secretion; and d) new pathogenic bacteria isolated from bronchial secretions; iii) a new and persistent (\>48 h) infiltrate on chest radiograph ([@b6-etm-05-01-0367]).

Antibiotic susceptibility test
------------------------------

Bacteria were identified using a Vitek-60 automated analysis system which was purchased from bioMérieux (Durham, UK). Susceptibility paper and susceptibility medium (MH medium) were purchased from Oxiod Ltd. (Basingstoke, UK) and Marcel Mérieux, respectively. Under sterile conditions, a disposable sterile sputum collector was used to collect secretion samples from the trachea through an endotracheal intubation catheter. A total of 127 sputum samples were cultured and a routine drug susceptibility test was performed within 15 min using the Vitek-60 analysis system and Kirby-Bauer disk diffusion method. The extended-spectrum β-lactamase (ESBL) strains were detected by double disk test. If more than two consecutive results were the same in one patient, we recorded the results of the sputum culture once; if the results were different, we recorded each result of the sputum culture.

Statistical analysis
--------------------

All data were analyzed using Stata software, version 9.0. Measurement data are denoted by median values and numeration data were presented as rate and constituent ratio.

Results
=======

Distribution of pathogens
-------------------------

The incidence of VAP was 24.59% (121/492). A total of 127 strains were detected from 121 VAP patients. Six patients were diagnosed with mixed infections. None were recurrent. Gram-negative bacteria, gram-positive bacteria and fungi accounted for 64.57% (82/127), 29.92% (38/127) and 5.51% (7/127) of the strains, respectively. The most common pathogens were *Acinetobacter baumannii, Escherichia coli, Stenotrophomonas maltophilia, Klebsiella pneumoniae and Pseudomonas aeruginosa* ([Table II](#t2-etm-05-01-0367){ref-type="table"}).

Drug resistance results of common pathogens
-------------------------------------------

The detection rates of ESBL-producing *Escherichia coli*, ESBL-expressing *Klebsiella pneumoniae* and methicillin-resistant *Staphylococcus aureus* (MRSA) were 58.82% (10/17), 41.67% (5/12) and 66.67% (4/6), respectively.

The gram-negative bacilli demonstrated multiple drug resistance. The 5 most commonly isolated strains were *Acinetobacter baumannii, Escherichia coli, Stenotrophomonas maltophilia, Klebsiella pneumoniae* and *Pseudomonas aeruginosa*. All of them, with the exception of *Acinetobacter baumannii*, were sensitive to cefoperazone/sulbactam*. Escherichia coli* and *Klebsiella pneumoniae* demonstrated no drug resistance to meropenem and imipenem; however, they had a high resistance to most penicillins and cephalosporins. All *Pseudomonas aeruginosa* isolates were sensitive to cefoperazone/sulbactam, imipenem, piperacillin/tazobactam, amikacin and levofloxacin; however, the drug resistance to meropenem was high (72.73%). All *Stenotrophomonas maltophilia* isolates were sensitive to cefoperazone/sulbactam, piperacillin/tazobactam and levofloxacin; 35.29% of them were resistant to cefoxitin and its drug resistance rate to other antibiotics was \>70% ([Table III](#t3-etm-05-01-0367){ref-type="table"}).

Gram-positive cocci had no drug resistance to vancomycin and linezolid; however, they demonstrated high drug resistance to penicillin-G, erythromycin, clindamycin and sulfamethoxazole. The positive percentage of β-lactamase was 76.32% (29/38) in 38 staphylococci. The 10 *Staphylococcus epidermidis* strains were resistant to oxacillin. The resistance to oxacillin was 88.89% (8/9) in other coagulase negative staphylococcus (CoNS) strains; however, all 6 *Staphylococcus aureus* strains demonstrated no drug resistance to oxacillin ([Table IV](#t4-etm-05-01-0367){ref-type="table"}). The 7 strains of *Candida albicans* were all susceptible to fluconazole.

Discussion
==========

The PICU is the centre of intensive care and treatment for critically ill children and invasive and complex techniques and equipment, including tracheal intubation and mechanical ventilation, are used frequently. Hamid *et al*([@b2-etm-05-01-0367]) reported that VAP occurrence was closely associated with the following factors: i) age of the patient \<1 year; ii) emergent intubation and iii) persistent and long-time sedation. Patients in the PICU often suffer from severe pathophysiological disorders and hypo-immunologic function. Intubation and mechanical ventilation are essential to maintain normal ventilation and gas exchange. The ventilator guarantees normal oxygenation; however, the airway mucosal destruction and barotrauma increases the risk of pathogenic colonization and infection in the respiratory system. We separated 127 strains of pathogens from 121 sputum samples collected from the lower respiratory tract. Gram-negative bacteria were the dominant pathogens and among them, the most frequent pathogens were *Acinetobacter baumannii, Escherichia coli, Stenotrophomonas maltophilia, Klebsiella pneumoniae* and *Pseudomonas aeruginosa. Staphylococcus epidermidis* was the most common gram-positive pathogen.

In recent years, the non-fermenters such as *Acinetobacter baumannii* and *Stenotrophomonas maltophilia*, have become increasingly prevalent. They have been the main pathogenic bacteria in hospital-acquired infection, particularly in VAP ([@b7-etm-05-01-0367],[@b8-etm-05-01-0367]). We report that non-fermenters accounted for 46.34% of the cases of VAP and among them the percentage of *Acinetobacter baumannii* was 25.61%. High drug resistance often occurred with *Acinetobacter baumanii* due to the high expression of AmpC enzyme, synthesis of OXA-23 carbapenemases, downregulation of the sensitivity of the efflux pump and production of penicillin-binding protein (PBP). At the same time, certain drug-resistant bacteria may transfer drug-resistant plasmids between each other, resulting in multi-drug resistance ([@b9-etm-05-01-0367],[@b10-etm-05-01-0367]). The current study demonstrated that *Acinetobacter baumannii* is only partly sensitive to aminoglycosides, quinolones, cefotaxime, piperacillin/tazobactam and cefoperazone/sulbactam and 100% resistant to carbapenems. Therefore, imipenem and meropenem are not the preferred antibiotics for *Acinetobacter baumannii*. The drug resistance rates to imipenem and meropenem were higher in other non-fermenters. The resistance rates of *Pseudomonas aeruginosa* to imipenem and meropenem were 0 and 72.73%, respectively, and in *Stenotrophomonas maltophilia,* they were 70.59 and 100%, respectively. These results indicate that there may be a natural drug resistance to these two antibiotics ([@b11-etm-05-01-0367],[@b12-etm-05-01-0367]). Therefore, it is necessary to stringently manage and control the use of carbapenems due to the decreased sensitivity of *Acinetobacter baumannii*, increased resistance of *Pseudomonas aeruginosa* and the natural drug resistance of *Stenotrophomonas maltophilia.*

The wide usage of β-lactam antibiotics in the clinic induces the production of ESBL in *Escherichia coli* and *Klebsiella pneumoniae*. ESBL may hydrolyze cephalosporin and transfect between bacteria, which promotes the transmission of drug resistance between pathogens ([@b13-etm-05-01-0367]). The present study revealed that the percentages of ESBL in *Escherichia coli* and *Klebsiella pneumoniae* were 58.82 and 41.67%, respectively. Although they were sensitive to carbapenems, aminoglycosides, quinolones and antibiotics combined with an enzyme inhibitor, they were highly resistant to penicillin and cephalosporin. The gram-positive coccus gained high resistance to penicillin; however, they were completely sensitive to vancomycin and linezolid. Therefore, vancomycin and linezolid are preferred in severe infection caused by *Staphylococcus aureus* and β-lactam, sulfamethoxazole, erythromycin and clindamycin antibiotics are no longer recommended in the treatment of severe gram-positive cocci infection ([@b14-etm-05-01-0367],[@b15-etm-05-01-0367]).

Fungal infection accounted for 5.51% of the cases of VAP in the current study. *Candida albicans* was the prime pathogen identified in fungal VAP and was sensitive to the majority of antifungal drugs. The factors that may be associated with fungal infections in children are low immune function, long-term usage of broad-spectrum antibiotics, unreasonable usage of glucocorticoids and invasive surgery ([@b16-etm-05-01-0367],[@b17-etm-05-01-0367]).

VAP acutely threatens patient survival in the PICU. Its pathogenic distribution and drug susceptibility are diverse across different centers; therefore, once VAP is diagnosed, the first choice is empirical antibiotic treatment according to previous data. As studies of drug susceptibility are reported, the choice of antibiotic may be performed more selectively.

The study was supported by National Natural Science Foundation of China (No. 30901327).

###### 

General data of the 121 VAP patients.

  Variables                            Number of patients   Rate (%)
  ------------------------------------ -------------------- ----------
  Gender                                                    
    Male                               75                   61.98
    Female                             46                   38.02
  VAP occurrence                                            
    \<5 days                           36                   29.75
    ≥5 days                            85                   70.25
  Basic diseases                                            
    Severe pneumonia                   39                   32.23
    Sepsis with ARDS                   17                   14.05
    Central nervous system infection   29                   23.97
    Trauma                             11                   9.09
    Drowning                           9                    7.44
    Drug poisoning                     7                    5.79
    Epilepsy                           3                    2.48
    Asthma                             2                    1.65
    Non-traumatic                                           
    intracranial hemorrhage            4                    3.31

VAP, ventilator-associated pneumonia; ARDS, acute respiratory distress syndrome.

###### 

Distribution of detected pathogens in the sputum of children with VAP.

  Pathogen                           Number of strains   Proportion (%)
  ---------------------------------- ------------------- ----------------
  Gram-negative bacteria             82                  64.57
    *Acinetobacter baumannii*        21                  25.61
    *Escherichia coli*               17                  20.27
    *Stenotrophomonas maltophilia*   17                  20.27
    *Klebsiella pneumoniae*          12                  16.22
    *Pseudomonas aeruginosa*         11                  9.46
    *Sphingomonas paucimobilis*      2                   2.70
    *Aeromonas hydrophila*           1                   1.35
    *Salmonella thompson*            1                   1.35
  Gram-positive bacteria             38                  29.92
    *Staphylococcus epidermidis*     10                  26.32
    Other CoNS                       9                   23.68
    *Streptococcus*                  7                   18.42
    *Staphylococcus aureus*          6                   15.79
    *Enterococcus*                   4                   10.53
    *Micrococcus*                    1                   2.63
    *Bacillus*                       1                   2.63
  Fungus                             7                   5.51
    *Candida albicans*               7                   5.51
  Total                              127                 100.00

VAP, ventilator-associated pneumonia; CoNS, coagulase negative staphylococcus.

###### 

Antimicrobial resistance patterns of common gram-negative bacteria isolated from the sputum of children with VAP.

  Drugs                     Pathogens (drug resistance rate, %)                              
  ------------------------- ------------------------------------- -------- -------- -------- --------
  Cefoperazone/sulbactam    57.14                                 0.00     0.00     0.00     0.00
  Cephazoline               100.00                                100.00   100.00   100.00   100.00
  Cefoxitin                 100.00                                50.00    35.29    50.00    100.00
  Amikacin                  80.95                                 11.76    100.00   0.00     0.00
  Levofloxacin              42.86                                 35.29    0.00     25.00    0.00
  Cefuroxime                100.00                                82.35    100.00   100.00   100.00
  Ceftazidime               100.00                                70.59    100.00   100.00   100.00
  Ampicillin                100.00                                100.00   100.00   100.00   100.00
  Cefpiramide               100.00                                76.47    100.00   100.00   0.00
  Gentamicin                100.00                                82.35    100.00   50.00    0.00
  Imipenem                  100.00                                0.00     70.59    0.00     0.00
  Meropenem                 100.00                                0.00     100.00   0.00     72.73
  Cefotaxime                61.90                                 70.59    100.00   41.67    0.00
  Piperacillin/tazobactam   80.95                                 0.00     0.00     25.00    0.00

VAP, ventilator-associated pneumonia.

###### 

Antimicrobial resistance patterns of staphylococci isolated from the sputum of children with VAP.

  Drugs                  Pathogens (drug resistance rate, %)           
  ---------------------- ------------------------------------- ------- -------
  Clindamycin            60.00                                 44.44   50.00
  Linezolid              0.00                                  0.00    0.00
  Ampicillin/sulbactam   100.00                                77.78   0.00
  Gentamicin             40.00                                 44.44   33.33
  Oxacillin              100.00                                88.89   0.00
  Rifampicin             20.00                                 11.11   0.00
  Sulfamethoxazole       90.00                                 55.56   66.67
  Vancomycin             0.00                                  0.00    0.00
  Moxifloxacin           0.00                                  0.00    0.00
  Erythromycin           90.00                                 55.56   83.33
  Furantoin              0.00                                  0.00    0.00
  Levofloxacin           0.00                                  33.33   33.33
  Penicillin-G           100.00                                88.89   83.33
  Tetracycline           40.00                                 22.22   0.00

VAP, ventilator-associated pneumonia; CoNS, coagulase negative staphylococcus.
